Immunotherapy for non-small cell lung cancer: current concepts and clinical trials
M Mayor, N Yang, D Sterman, DR Jones… - European journal of …, 2015 - academic.oup.com
M Mayor, N Yang, D Sterman, DR Jones, PS Adusumilli
European journal of cardio-thoracic surgery, 2015•academic.oup.comRecent successes in immunotherapeutic strategies are being investigated to combat
cancers that have less than ideal responses to standard of care treatment, such as non-
small-cell lung cancer. In this paper, we summarize concepts and the current status of
immunotherapy for non-small cell lung cancer, including salient features of the major
categories of immunotherapy—monoclonal antibody therapy, immune checkpoint blockade,
immunotoxins, anticancer vaccines, and adoptive cell therapy.
cancers that have less than ideal responses to standard of care treatment, such as non-
small-cell lung cancer. In this paper, we summarize concepts and the current status of
immunotherapy for non-small cell lung cancer, including salient features of the major
categories of immunotherapy—monoclonal antibody therapy, immune checkpoint blockade,
immunotoxins, anticancer vaccines, and adoptive cell therapy.
Abstract
Recent successes in immunotherapeutic strategies are being investigated to combat cancers that have less than ideal responses to standard of care treatment, such as non-small-cell lung cancer. In this paper, we summarize concepts and the current status of immunotherapy for non-small cell lung cancer, including salient features of the major categories of immunotherapy—monoclonal antibody therapy, immune checkpoint blockade, immunotoxins, anticancer vaccines, and adoptive cell therapy.
Oxford University Press